000			04044nam a22004935i 4500
001			978-3-540-34447-6
003			DE-He213
005			20161121230708.0
007			cr nn 008mamaa
008			100301s2006 gw | s |||| 0|eng d
020			_a9783540344476 _9978-3-540-34447-6
024	7		_a10.1007/3-540-34447-0 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
245	1	0	_aInsights into Receptor Function and New Drug Development Targets _h[electronic resource] / _cedited by Michael Conn, Claude Kordon, Yves Christen.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2006.
300			_aXV, 202 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aResearch and Perspectives in Endocrine Interactions
505	0		_aMolecular and functional diversity of the TRPC family of ion channels. TRPC channels and their role in ROCE/SOCE -- Functional Rescue of Misfolded Receptor Mutants -- Obesity-related mutations of leptin and melanocortin receptors -- cAMP- and cGMP-dependent control of lipolysis and lipid mobilization in humans: putative targets for fat cell management -- Central Neuropeptide Receptors Involved in Water Balance: Application to Apelin -- Targeting regulators of G protein signaling (RGS proteins) to enhance agonist specificity -- Dimeric GPCRs: what did we learn from the metabotropic glutamate receptors? -- Guiding principles applied in the design of GPCR-selective hypothalamic hormone agonists and antagonists -- Mutations in G proteins and G protein-coupled receptors in human endocrine diseases -- A molecular dissection of the glycoprotein hormone receptors -- Receptor Tyrosine Kinases as Targets for Cancer Therapy Development -- Targets for pituitary tumor therapy -- The endogenous cannabinoid system in the control of food intake and energy balance.
520			_aG-Protein Coupled receptors (GPCRs) and other receptors are significant targets for drug discovery, due to their roles in fundamental physiological processes. Among these roles are: regulation of growth, food intake, reproduction, water balance, sensory perception, blood pressure and heart rate. GPCR-directed drugs account for approximately $40 billion in sales and, of drugs at market, approximately 70% target GPCR function. The availability of combinatorial chemistry coupled with high throughput screening techniques have facilitated discovery of peptidic and non-peptidic ligands of membrane receptors. Mutant receptor models have revealed their role in health and disease and provided insight to new therapeutic approaches, based on control of protein trafficking. Understanding receptor-receptor interactions has provided one mechanism for receptor cross-talk and revealed unexpected interactions. The completion of the human genome has identified a new source of therapeutic targets: "orphan receptors" with unknown functions and yet-to-be discovered ligands. Some orphans have now been identified as ghrelin, nociceptin, apelin, and urocortin. This finding, along with important technologies to develop ligands with desirable characteristics, including peptidomimetics is likely to further accelerate interest in this area.
650		0	_aMedicine.
650		0	_aPharmacology.
650		0	_aEndocrinology.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aBiomedicine general.
650	2	4	_aEndocrinology.
700	1		_aConn, Michael. _eeditor.
700	1		_aKordon, Claude. _eeditor.
700	1		_aChristen, Yves. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540344469
830		0	_aResearch and Perspectives in Endocrine Interactions
856	4	0	_uhttp://dx.doi.org/10.1007/3-540-34447-0
912			_aZDB-2-SBL
950			_aBiomedical and Life Sciences (Springer-11642)
999			_c502596 _d502596